Aiforia Technologies

03/09/2026

⭐ AI is transforming pathology, and the people leading the change deserve recognition.

Artificial Intelligence is reshaping the future of healthcare, with pathology at the forefront of this transformation. While AI has immense potential, true progress happens with the help of people who believe in its high value in pathology, take a step forward, and navigate the change.

That’s why we’re proud to bring back the ✨Aiforia AI Navigator Award✨ for its second year, celebrating the individuals and teams who are helping advance AI in pathology and making a lasting impact on the industry. By pioneering new approaches to bringing innovation into daily practice, these forerunners are helping to shape the future of diagnostics and, ultimately, improve patient outcomes.

🏆 We’re excited to continue this journey and celebrate the people who are driving AI forward. Join us at the Aiforia AI Navigator Award ceremony during the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. Stay tuned as we introduce this year’s award and the inspiring people behind the progress!

Together, we’re building the future of pathology.

01/09/2026

We’re excited to welcome Federico Sebastiani as our CCO, starting from today. 👏🏻

With 25+ years of leadership across genomics, molecular diagnostics, and digital health, Federico’s expertise in global commercial strategy and strategic partnerships will be instrumental as we scale international adoption and advance AI-powered pathology diagnostics.

Join us in welcoming Federico to the team!

📄 Read more: https://hubs.la/Q04w1txw0

31/08/2026

⚡ Experience the next-generation AI technology platform at

Staining, scanner differences, and poor sample quality can all complicate digital pathology workflows. At the 38th European Congress of Pathology (ECP) 2026, organized by ESP European Society of Pathology, learn how Aiforia's Foundation Engine powers AI solutions to operate with high reliability across diverse real-world conditions.

Whether you are looking to deploy pre-trained clinical AI models or accelerate custom-model creation in Aiforia® Create, our proprietary Foundation Engine technology helps you achieve results faster and with less training data.

Stop by our booth number 104 to:
📈 Explore our expanding range of AI solutions powered by Foundation Engine technology
🖥️ Learn about real-world Aiforia® Clinical Platform use cases and performance results
👤 Connect with our team to discover how this technology elevates AI model training in Aiforia® Create

🔗 Book a live demo in Stockholm: https://hubs.la/Q04vRRBW0

28/08/2026

ENG: Aiforia’s Half-Year Financial Report January‒June 2026 has been published.

CEO, Jukka Tapaninen: “In the first half of 2026, Aiforia continued to strengthen its market position as a pioneer in AI-assisted pathology. Throughout the period, we bolstered our European expansion by signing new agreements in Italy, Spain, and France, among other countries. The financing arrangements implemented during the period support Aiforia's growth strategy and strengthen our ability to invest in accelerating commercial growth and product development.”

Read more and get the report: https://hubs.la/Q04vD8YN0
🎥 Follow the live webcast today at 10:00 am EEST: https://hubs.la/Q04vDg4J0

FIN: Aiforian puolivuosikatsaus tammi–kesäkuulta 2026 on julkaistu.

Toimitusjohtaja Jukka Tapaninen: “Vuoden 2026 ensimmäisellä puoliskolla Aiforia jatkoi markkina-asemansa vahvistamista tekoälyavusteisen patologian edelläkävijänä. Läpi kauden vahvistimme yhtiön laajentumista Euroopassa solmimalla uusia sopimuksia muun muassa Italiassa, Espanjassa ja Ranskassa. Katsauskauden aikana toteutetut rahoitusjärjestelyt tukevat Aiforian kasvustrategiaa ja vahvistavat valmiuksiamme investoida kaupallisen kasvun vauhdittamiseen sekä tuotekehitykseen.”

Lue lisää ja lataa raportti: https://hubs.la/Q04vDdkB0
🎥 Seuraa englanninkielistä webcast-tilaisuutta tänään klo 10.00: https://hubs.la/Q04vDg4J0

25/08/2026

📢 Aiforia and Stratipath today announced a strategic partnership.

This collaboration aims to provide pathologists and oncologists with broader access to validated AI-powered diagnostic and prognostic tools and sets the stage for a long-term commercial relationship between the two companies. As part of the partnership, Aiforia and Stratipath will integrate Stratipath Breast solution into the Aiforia Clinical Platform, enabling laboratories to access both companies’ breast cancer AI applications through a single, streamlined user interface.

“Combining our solutions gives pathologists and oncologists faster access to validated, high-impact AI tools within a workflow they already trust. We look forward to our collaboration with Stratipath," said Jukka Tapaninen, CEO of Aiforia.

“Together with Aiforia, we bring risk profiling to more hospitals, delivering results in minutes rather than weeks. Precision diagnostics should be standard of care, not a privilege, and this partnership takes us a step closer,” said Fredrik Wetterhall, CEO and Co-founder of Stratipath.

🔗 Read the full press release: https://hubs.la/Q04v8Y4v0

🖥️ Heading to in Stockholm? Stop by booth #104 on September 13–15 to experience our combined solution firsthand.

Aiforia

24/08/2026

The 38th European Congress of Pathology (ECP) 2026, organized by the ESP European Society of Pathology in Stockholm, Sweden, is coming up next month 🇸🇪

Are you ready to experience the comprehensive portfolio of AI solutions through a live demo? Visit Aiforia's booth number 104 to see the Aiforia® Platform in action and discover:

📈 Growing portfolio of Aiforia's AI solutions
🖥️ Aiforia's Foundation Engine technology
📊 How AI-assisted image analysis can increase efficiency, precision, and consistency in the pathology workflow

Connect with our experts to discover more about Aiforia's solutions. Book a meeting in advance or learn more already now: https://hubs.la/Q04tYS530

18/08/2026

🇮🇹🧬 Migliorare la ricerca sul mesotelioma con il deep learning

Il mesotelioma è un tumore altamente aggressivo e la complessità del suo microambiente tissutale rende l'analisi manuale delle immagini un'attività estremamente lunga e impegnativa.

Scopri il nostro caso di studio con il Prof. Mauro Papotti e la http://Prof.ssa Eleonora Duregon dell'Università degli Studi di Torino, che illustra come i ricercatori abbiano utilizzato Aiforia® Create per sviluppare un modello di intelligenza artificiale in grado di riconoscere i sottotipi di mesotelioma attraverso l'analisi della colorazione alla reticolina.

Leggi il caso di studio e scopri come la piattaforma Aiforia può automatizzare le attività ripetitive di quantificazione, ottimizzare i flussi di lavoro e accelerare la ricerca oncologica.
https://hubs.la/Q04tjVm70



__________
🧬 Enhancing mesothelioma research with deep learning. Read our case study with Prof. Mauro Papotti and Prof. Eleonora Duregon from the University of Turin to find out how researchers utilized Aiforia® Create to build an AI model for mesothelioma subtype recognition with reticulin stain detection: https://hubs.la/Q04tjVm70

A research team from the University of Turin used Aiforia® Create to build an AI model for mesothelioma subtyping with reticulin stain. Read more or watch the video interview.

12/08/2026

🇫🇷📈 Comment l’IA trouve-t-elle progressivement sa place en anatomopathologie ?

Dans cet article, le Pr Catherine Guettier partage son regard sur l’évolution de l’intelligence artificielle en anatomopathologie et sur les conditions nécessaires à son intégration dans les hôpitaux français.

Un retour d’expérience éclairant sur les enjeux d’adoption, de confiance, d’évaluation clinique et d’intégration dans la pratique diagnostique.

Découvrez l’article ici :
https://hubs.ly/Q04sKd1R0



__________
📈 How is AI transforming diagnostic pathology in France? In this guest post, Dr. Catherine Guettier shares her front-row perspective on integrating AI workflows into French hospitals from evaluation criteria to routine adoption: https://hubs.ly/Q04sKd1R0

03/08/2026

Can healthcare institutions adopt top-tier AI without getting trapped by vendor lock-in or workflow friction?

The answer is yes. ✅

Fimlab, Finland's largest healthcare laboratory service provider, is proving it by equipping pathologists with an AI-driven decision-support tool, directly inside their daily diagnostic workflows.

How? By establishing a standards-based, interoperable architecture among Softwarepoint (LVMS), Philips (slide scanners), and Aiforia (AI platform).

With the Aiforia® Breast Cancer Suite AI solution at the center of this workflow, Fimlab's pathology team benefits from:
✔️ Automated full-sample Ki67 scoring (filtering out control/non-tumor tissue automatically)
✔️ Reduced turnaround times and enhanced diagnostic confidence
✔️ Seamless data flow without manual entry errors

Learn how seamless multi-vendor interoperability is powering Fimlab's high-volume pathology lab: https://hubs.la/Q04rC1zZ0

Learn how Fimlab has scaled AI-driven breast cancer diagnostics with an open ecosystem featuring Aiforia, Philips, and Softwarepoint.

31/07/2026

📢 NEWS: Aiforia has secured €20 million in venture debt financing from the European Investment Bank (EIB), supported by the European Commission’s InvestEU program.

As our CEO, Jukka Tapaninen, put it: "This financing strengthens Aiforia's financial position and supports the implementation of our strategy. With this financing, we can accelerate product development, expand our commercial operations internationally, and advance our goal of improving patient care through AI-powered image analysis solutions."

EIB Vice-President Karl Nehammer also highlighted the importance of European innovation in healthcare: "The solutions developed by Aiforia strengthen Europe’s competitiveness, while giving an innovative EU company the opportunity to succeed on the global stage."

What does this mean for our customers, partners, and the whole digital pathology industry?
⚙️ Accelerated product development for both current and upcoming AI solutions, delivering precision and speed directly into the hands of pathologists
🌍 Expanding our international presence to offer even stronger local expertise in new markets and robust ongoing support for Aiforia users worldwide
🏥 Backing from EIB reinforces both Europe's competitiveness and our trajectory as a European company and a market leader in CE-IVD marked AI solutions for digital pathology

🔗 Read the full press release from the European Investment Bank's website: https://hubs.la/Q04rv12c0

The European Investment Bank (EIB) has signed a €20 million venture debt financing agreement with Finnish life-science technology innovator Aiforia. The funding will support the further development of the company’s AI powered platform, designed to support pathologists in digital tissue analysis ...